Merck and GE Healthcare announce agreement for use of Flutemetamol

Merck (MRK) and GE Healthcare announced a clinical study collaboration, license and supply agreement for use of Flutemetamol, an investigational positron emission tomography. or PET, imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme inhibitor and Merck's lead investigational candidate for Alzheimer's disease. GE Healthcare is a unit of General Electric Company (GE)